Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

69732

Millipore

Lithium mupirocin Supplement

suitable for microbiology,

Selectively inhibits the growth of lactic acid bacteria

Synonyme(s) :

Lithium mupirocin solution, Li-MUP, MUP supplement

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C26H43LiO9
Numéro CAS:
Poids moléculaire :
506.56
Numéro MDL:
Code UNSPSC :
41171614
ID de substance PubChem :
Nomenclature NACRES :
NA.85

Agence

ISO 29981:2010

Niveau de qualité

Stérilité

sterile (Filtered and Aseptic Handled)
sterile

Forme

liquid

Durée de conservation

limited shelf life, expiry date on the label

Application(s)

environmental
food and beverages

microbiology

Température de stockage

2-8°C

Adéquation

Lactobacillus spp.
Lactococcus spp.
Leuconostoc spp.
Streptococcus spp.

Chaîne SMILES 

[Li+].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]2CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)[C@H](O)[C@@H]2O

InChI

1S/C26H44O9.Li/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27;/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29);/q;+1/p-1/b16-13+;/t17-,18-,19-,20-,21-,24+,25-,26-;/m0./s1

Clé InChI

XFIKMPRBSORKQP-JATHGWPISA-M

Description générale

Lithium mupirocin is isolated from Pseudomonas fluorescens. At lower concentrations, it has bacteriostatic characteristics, while at higher concentrations it is bacteriocidal. Mupirocin is active against gram-positive bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA), Lactobacilli, Lactococci, Streptococci and Leuconostocs. Mupirocin has been used to study mupirocin resistance in Mycoplasma bacteria. Mupirocin inhibits the isoleucyl-tRNA synthetase, which finally results in inhibition of protein and RNA synthesis. Mupirocin lithium salt is freely soluble in water.

Application

Lithium mupirocin supplement is used for selective enumeration of Bifidobacteria from fermented milk products along with the TOS-propionate agar according to ISO 29981:2010 and IDF 220:2010

Composants

Composition:
(5ml, sufficient for 100 ml medium)
Mupirocin 5 mg
sterile distilled water 5.0 ml

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Variation, viability and validity of bifidobacteria in fermented milk products.
Raeisi, Shahram Naghizadeh, et al.
Food Control, 34, 691-697 (2013)
J Gilbart et al.
Antimicrobial agents and chemotherapy, 37(1), 32-38 (1993-01-01)
Mupirocin resistance in Staphylococcus aureus results from changes in the target enzyme, isoleucyl-tRNA synthetase (IRS). Twelve strains of S. aureus comprising four susceptible (MICs < or = 4 micrograms/ml), four intermediate level-resistant (MICs between 8 and 256 micrograms/ml), and four
Hyukmin Lee et al.
Diagnostic microbiology and infectious disease, 75(3), 308-312 (2013-01-23)
In this study, we determined the prevalence of mupirocin and antiseptics resistance in methicillin-resistant Staphylococcus aureus (MRSA) at a secondary- and a tertiary-care hospital in Korea. Mupirocin susceptibility test, ileS gene sequencing, and polymerase chain reaction for mupA, qacA/B, and
Emergence of methicillin-resistant Staphylococcus aureus ST239 with high-level mupirocin and inducible clindamycin resistance in a tertiary care center in Chennai, South India.
Nagarajan Abimanyu et al.
Journal of clinical microbiology, 50(10), 3412-3413 (2012-08-03)
Yi-Yuan Chiu et al.
BMC genomics, 13 Suppl 7, S21-S21 (2013-01-11)
To discover a compound inhibiting multiple proteins (i.e. polypharmacological targets) is a new paradigm for the complex diseases (e.g. cancers and diabetes). In general, the polypharmacological proteins often share similar local binding environments and motifs. As the exponential growth of

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique